{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Highlights Promising Treatment Approach for Children with Relapsed/Refractory JMML ((Non-Physician Credit))

Activity Steps

Description

The certificate for this activity is for NON-PHYSICIANS.

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Explain the importance of exploring novel treatment options for juvenile myelomonocytic leukemia (JMML).
  2. Summarize the results of the clinical trial investigating the efficacy and safety of trametinib for the treatment of children with relapsed or refractory JMML.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Test Code: OTN1024
Published: October 2024
Expires: 9/30/2026
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Categories: Hematology , Oncology
Specialties: Hematology, Oncology